Search results
Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So. | The Motley Fool
The Motley Fool· 23 hours agoCRISPR Therapeutics (CRSP 2.24%) closed last week down 8.5% after reporting first-quarter "earnings"...
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
Zacks via Yahoo Finance· 3 days agoRecently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes...
CRISPR can treat common form of inherited blindness, early data hint
Live Science via Yahoo News· 24 hours agoA photo shows two male doctors in surgery garb as one preps a long needle for a procedure. A patient...
How Gene Editing Therapies Could Go Beyond Rare Diseases
Forbes· 9 hours agoEarlier this year, a group of scientists in the Netherlands used the gene editing tool CRISPR to...
New strategy suppresses unwanted deletion events to make genome editing safer and more precise
Phys.org· 21 hours agoThis approach tackles a critical issue with CRISPR technology: the act of slicing the genome at...
Earnings call: Intellia Therapeutics reports robust Q1 progress By Investing.com
Investing.com· 7 days agoIntellia Therapeutics (NASDAQ: NASDAQ:NTLA) has made significant progress in the first quarter of...
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
Zacks via Yahoo Finance· 7 days agoCRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims...
CRISPR-based gene editing treatment shows promise for rare eye disorder
MedicalNewsToday via AOL· 7 days agoResearchers at Oregon Health & Science University used an experimental CRISPR-based gene editing...
Gene Editing Breakthrough: CRISPR Improves Vision in Clinical Trial
SciTechDaily· 3 days agoMass Eye and Ear researchers say their findings support continued research and clinical trials of ...
CRISPR Therapeutics’ (CRSP) Neutral Rating Reiterated at Cantor Fitzgerald
ETF DAILY NEWS· 3 days agoCantor Fitzgerald reissued their neutral rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a research note issued to investors on Thursday, Benzinga reports ...